Literature DB >> 22261167

Response to alemtuzumab in FIP1L1/PDGFRA-negative hypereosinophilic myocarditis on serial cardiac magnetic resonance imaging.

Faisal F Syed1, Jonathan S Bleeker, James Glockner, Animesh Pardanani, Leslie T Cooper.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22261167     DOI： 10.1016/j.jacc.2011.06.078

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  3 in total

1.  Rapid left ventricular thickening and thrombus caused by FIP1L1/PDGFRA-negative hypereosinophilic syndrome.

Authors:  Ho-Young Yhim; Sang-Rok Lee
Journal:  Tex Heart Inst J       Date:  2013

Review 2.  Novel targeted therapies for eosinophilic disorders.

Authors:  Michael E Wechsler; Patricia C Fulkerson; Bruce S Bochner; Gail M Gauvreau; Gerald J Gleich; Tim Henkel; Roland Kolbeck; Sameer K Mathur; Hector Ortega; Jatin Patel; Calman Prussin; Paolo Renzi; Marc E Rothenberg; Florence Roufosse; Dagmar Simon; Hans-Uwe Simon; Andrew Wardlaw; Peter F Weller; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2012-09       Impact factor: 10.793

3.  Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document.

Authors:  Enrico Ammirati; Maria Frigerio; Leslie T Cooper; Paolo G Camici; Eric D Adler; Cristina Basso; David H Birnie; Michela Brambatti; Matthias G Friedrich; Karin Klingel; Jukka Lehtonen; Javid J Moslehi; Patrizia Pedrotti; Ornella E Rimoldi; Heinz-Peter Schultheiss; Carsten Tschöpe
Journal:  Circ Heart Fail       Date:  2020-11-12       Impact factor: 8.790
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.